Back to Search Start Over

Clinical Outcomes, Treatment Toxicity, and Health Care Utilization in Older Adults with Aggressive Non-Hodgkin Lymphoma.

Authors :
Johnson, P Connor
Johnson, P Connor
Yi, Alisha
Horick, Nora
Amonoo, Hermioni L
Newcomb, Richard A
Lavoie, Mitchell W
Rice, Julia
Reynolds, Matthew J
Ritchie, Christine S
Nipp, Ryan D
El-Jawahri, Areej
Johnson, P Connor
Johnson, P Connor
Yi, Alisha
Horick, Nora
Amonoo, Hermioni L
Newcomb, Richard A
Lavoie, Mitchell W
Rice, Julia
Reynolds, Matthew J
Ritchie, Christine S
Nipp, Ryan D
El-Jawahri, Areej
Source :
The oncologist; vol 26, iss 11, 965-973; 1083-7159
Publication Year :
2021

Abstract

BackgroundAlthough balancing treatment efficacy with risks of complications is critical for older adults with aggressive non-Hodgkin lymphoma (NHL), few studies have described these patients' clinical outcomes, rates of toxicities, and health care utilization.MethodsWe conducted a retrospective analysis of adults ≥65 years diagnosed with aggressive NHL and receiving systemic therapy at Massachusetts General Hospital from April 2000 to July 2020. We abstracted patient characteristics, clinical outcomes, treatment toxicity, unplanned hospitalizations, and intensive care unit (ICU) admissions within 6 months of treatment initiation from the medical record. Using multivariable logistic regression, we examined factors associated with rates of grade 3+ nonhematologic toxicity and unplanned hospitalization.ResultsAmong 295 patients (median age, 73 years; 39.0% female), 5-year overall survival (OS) was 74.2%. Five-year OS by age group (65-69, 70-74, 75-79, and 80+ years) was 82.2%, 72.0%, 73.6%, and 66.4%, respectively. Overall, 42.4% experienced grade 3+ toxicity, with 8.1% experiencing grades 4-5. The rates of unplanned hospitalization and ICU admission were 41.0% and 6.1%, respectively. In multivariable analysis, hypoalbuminemia (odds ratio [OR], 4.29; p < .001) and high comorbidity score (OR, 4.22; p < .001) were associated with likelihood of grade 3+ toxicity. Hypoalbuminemia (OR, 2.83; p = .003), high comorbidity score (OR, 3.93; p = .001), and receipt of EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin; OR, 5.45; p = .012) were associated with likelihood of unplanned hospitalization.ConclusionsThe majority of older adults receiving upfront therapy for aggressive NHL survive beyond 5 years, yet nearly half experience substantial treatment toxicities and unplanned hospitalizations. Our findings underscore the need for supportive care interventions to enhance the care experience of this population.Implications for practi

Details

Database :
OAIster
Journal :
The oncologist; vol 26, iss 11, 965-973; 1083-7159
Notes :
application/pdf, The oncologist vol 26, iss 11, 965-973 1083-7159
Publication Type :
Electronic Resource
Accession number :
edsoai.on1391592041
Document Type :
Electronic Resource